Immunic (IMUX) investor relations material

Company overview and financials

• Focused on developing first-in-class oral therapies for chronic inflammatory and autoimmune diseases, especially multiple sclerosis (MS) and gastrointestinal disorders.

• Cash balance of $186.6 million as of March 31, 2026; 13,621,526 shares outstanding as of April 30, 2026.

• Led by an experienced management team with a track record in drug development and commercialization.

Clinical pipeline and programs

• Vidofludimus calcium (IMU-838) is the lead asset, targeting both relapsing and progressive forms of MS, with phase 3 ENSURE trials fully enrolled and top-line data expected by end of 2026.

• Phase 2 CALLIPER trial in progressive MS (PMS) showed a 24% risk reduction in confirmed disability worsening, with a more pronounced 31% reduction in primary progressive MS (PPMS).

• IMU-856 is an oral SIRT6 modulator for gastrointestinal diseases, showing proof-of-concept in celiac disease and dose-dependent increases in GLP-1.

Market opportunity and competitive landscape

• MS market is valued at $20 billion and growing 4% annually, with oral therapies expected to maintain over one-third market share by 2032.

• Vidofludimus calcium has a peak sales potential of $3-7 billion across MS indications, aiming to be the first oral DMT approved for both relapsing and progressive MS.

• PPMS remains underdiagnosed and undertreated, with only one approved therapy and a global market estimated at $6 billion.